Table 2 Comparison between MS patients with both variables showing significant associations at baseline visit vs. MS patients without both of them.

From: Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab

Baseline EDSS

Baseline EBNA-1 IgG titers

NEDA-3

Clinical responders

Therapeutic failure

 < 3.0 (1.0–2.5)

 < 23,3 AU

28/43 (65.1%)

34/43 (79.1%)

2/43 (4.6%)

 > 3.0 (3.5–7.5)

 > 23,3 AU

8/35 (22.9%)

14/35 (40.0%)

13/35 (37.1%)

 

p value

0.0002

0.0004

0.0003

 

O.R

6.3

5.7

12.1

Back to article page